Seeking Alpha’s roundup of statements, announcements and remarks that could impact markets, sectors and individual stocks.
- Kenvue (NYSE:KVUE) management spoke with HHS Secretary Robert Kennedy Jr. to try to get Tylenol use off his list of suspected causes of autism.
“We engaged in a scientific exchange with the secretary and members of his staff as it relates to the safety of our products,” Kenvue said in an emailed statement, according to Bloomberg. “We continue to believe that taking acetaminophen does not cause autism, and global health regulators, independent public health organizations, and medical professionals agree.”
HHS is expected to release a report later this month about the suspected root causes of autism, which include taking acetaminophen during pregnancy. Acetaminophen is marketed by Kenvue under the name Tylenol.
- A CDC vaccine panel presentation slated for next week will link COVID vaccines to the deaths of 25 children, according to the Washington Post.
The claim is reportedly based on data submitted to the FDA’s Vaccine Adverse Event Reporting System, CNBC added.
In a statement to CNBC, Moderna said that safety monitoring systems in the U.S., Australia, Canada, and Europe have not indicated “any new or undisclosed safety concerns in children or in pregnant women.”
Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and Novavax (NASDAQ:NVAX) are the three leading COVID vaccine makers for the U.S. market.
- Fintech Lendbuzz (LBZZ), which specializes in auto loans, has filed for an IPO.
In an SEC filing on Friday, Lendbuzz didn’t disclose terms but indicated in a filing fee schedule that it was looking to raise up to $100 million, a figure that could be a placeholder and subject to change.
Lead bookrunners on the deal are Goldman Sachs, J.P. Morgan, RBC Capital Markets, and Mizuho. Lendbuzz hopes to list its shares on Nasdaq under the symbol LBZZ.